Drugs / GENEVAX-HIV
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00002232 | — | HIV infectious disease | Wyeth-Lederle Vaccines | Completed | No outcome recorded |
| Phase 1 | NCT00002231 | — | HIV infectious disease | Wyeth-Lederle Vaccines | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GENEVAX-HIV | “The purpose of this study is to see if it is safe to give GENEVAX-HIV, a new HIV vaccine, to HIV-negative volunteers.” NCT00002231 ↗1“GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine” NCT00002232 ↗ |
| Known as | APL 400-003 | “GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine” NCT00002232 ↗1“GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine” NCT00002231 ↗ |
| Modality | Vaccine | “Candidate DNA Vaccine” NCT00002231 ↗ |
| Route | Intramuscular | “Delivered Intramuscularly” NCT00002231 ↗ |